CLINICAL TRIALS PROFILE FOR DAROLUTAMIDE
✉ Email this page to a colleague
All Clinical Trials for DAROLUTAMIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02200614 ↗ | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer | Completed | Orion Corporation, Orion Pharma | Phase 3 | 2014-09-12 | The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer. |
| NCT02200614 ↗ | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer | Completed | Bayer | Phase 3 | 2014-09-12 | The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer. |
| NCT02799602 ↗ | ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | Active, not recruiting | Orion Corporation, Orion Pharma | Phase 3 | 2016-11-30 | The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer. |
| NCT02799602 ↗ | ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | Active, not recruiting | Bayer | Phase 3 | 2016-11-30 | The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer. |
| NCT03004534 ↗ | A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide | Completed | Bayer | Early Phase 1 | 2017-09-05 | The purpose of this study is to evaluate the effect of short-term treatment with darolutamide on breast cancer cells (i.e., how the treatment may change the genes or proteins in breast cancer cells) and to evaluate its safety and the way it is tolerated by subjects. The intent is to study these changes in order to have a better understanding of the potential use of darolutamide for women with EBC, know which patients are likely or unlikely to respond to this treatment, and determine how darolutamide may be combined with other anti-cancer drugs. |
| NCT03004534 ↗ | A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide | Completed | Translational Research in Oncology | Early Phase 1 | 2017-09-05 | The purpose of this study is to evaluate the effect of short-term treatment with darolutamide on breast cancer cells (i.e., how the treatment may change the genes or proteins in breast cancer cells) and to evaluate its safety and the way it is tolerated by subjects. The intent is to study these changes in order to have a better understanding of the potential use of darolutamide for women with EBC, know which patients are likely or unlikely to respond to this treatment, and determine how darolutamide may be combined with other anti-cancer drugs. |
| NCT03177187 ↗ | Combination Study of AZD5069 and Enzalutamide. | Recruiting | Astellas Pharma Inc | Phase 1/Phase 2 | 2017-11-13 | ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC). The investigators will be investigating the safety and toxicity of the combination. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DAROLUTAMIDE
Condition Name
Clinical Trial Locations for DAROLUTAMIDE
Trials by Country
Clinical Trial Progress for DAROLUTAMIDE
Clinical Trial Phase
Clinical Trial Sponsors for DAROLUTAMIDE
Sponsor Name
